Numerous medication classes of drugs such as hypoglycemic agents, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), renin-angiotensin system (RAS) blockers, sodium-glucose cotransport protein-2 inhibitors (SGLT2i), and glucagon-like peptide-1 receptor (GLP1R) agonists are available in the market to beneficially cure diabetes and DKD [15]. This evidence concerns the gene ACE and diabetic kidney disease.